针对BRAF突变转移性黑色素瘤的向治疗或免疫治疗:西班牙中心十年的经验
Chen Sun1, Sofia España2, Nina Richarz3
1Department of Radiation Oncology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Frontiers in oncology
|March 7, 2024
概括
对于晚期BRAF突变黑色素瘤,一线免疫疗法与向治疗 (BRAF/MEKi) 相比,显著改善了无进展生存率 (PFS) 和整体生存率 (OS). 向治疗显示出更高的客观响应率 (ORR).
科学领域:
- 在瘤学瘤学.
- 黑色素瘤研究 黑色素瘤研究
- 癌症治疗方法 癌症治疗方法
背景情况:
- 先进的BRAF突变黑色素瘤治疗主要依赖于向治疗和免疫治疗.
- 这些一线治疗和关键预后因素的比较影响仍然不完全理解.
研究的目的:
- 评估一线免疫治疗与针对性治疗 (BRAF/MEKi) 在晚期BRAF突变黑色素瘤中的有效性.
- 确定影响该患者群体生存结果的预后因素.
主要方法:
- 140名晚期黑色素瘤患者病历 (2011-2021) 的回顾性审查.
- 免疫疗法和BRAF/MEKi组之间的客观反应率 (ORR),无进展生存率 (PFS) 和整体生存率 (OS) 的比较.
- 使用考克斯回归模型进行预测因素评估.
主要成果:
- 在BRAF突变黑色素瘤中,免疫疗法比向治疗 (PFS: 11.5个月,OS: 16.4个月) 产生了显著更长的PFS (19.2个月) 和OS (33.4个月).
- 与免疫疗法 (43.8%) 相比,向治疗显示出更高的ORR (70%).
- ECOG性能状况,大脑转移和升高的LDH水平是PFS和OS的显著预后因素.
结论:
- 第一线免疫疗法在高级BRAF突变黑色素瘤中提供了优越的PFS和OS益处,而不是针对性的BRAF/MEKi疗法.
- 虽然向治疗实现了更高的初始响应率,但免疫治疗显示出更好的长期生存结果.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Tumor Immunotherapy
524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


